Sabby Management’s Astria Therapeutics ATXS Stock Holding History

Sabby Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-18,004	Closed	-$231K	–	161
2020 Q4	$231K	Buy	+18,004	New	+$321K	0.04%	82

Other funds holding ATXS

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sabby Management's ATXS Position: Q1 2021 in Review

Sabby Management sold out of Astria Therapeutics (ATXS) in Q1 2021, closing a stake of 18,004 shares — an estimated $231K sold.

Sabby Management first reported a position in ATXS in Q4 2020 and held it in 1 quarter. The position peaked at $231K in Q4 2020. 61 funds tracked by Wall St. Rank hold ATXS as of Q1 2021.

Sabby Management reported no remaining Astria Therapeutics position as of Q1 2021 after selling out during the quarter.
Sabby Management sold 18,004 Astria Therapeutics shares in Q1 2021, an estimated $231K.
Sabby Management first reported a position in Astria Therapeutics in Q4 2020 and held it in 1 quarter.
Sabby Management's Astria Therapeutics position peaked at $231K in Q4 2020.
61 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2021.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.